A Tool Kit for Action
The 2020 U.S. presidential election campaign season opens opportunities for IDSA and HIVMA members to speak with candidates by attending events hosted by them or their supporters, attending forums hosted by external organizations, or other activities. While IDSA and HIVMA are non-partisan organizations and do not endorse political candidates, we are eager to educate candidates about ID and HIV issues and to hear and influence their plans and positions on the issues that matter to IDSA and HIVMA members and their patients We encourage you to ask candidates or their staff questions about ID and HIV priorities. Click here to view a petition signed by over 500 members of IDSA, HIVMA, and PIDS urging all presidential candidates to prioritize responses to infectious diseases threats.
- Use social media to ask candidates about their positions. Click here for our #2020questions social media toolkit.
- Check out the candidates’ websites for information about events in your community.
- Keep questions clear and succinct.
- Bring colleagues with you.
- Share a photo of yourself in action with IDSA and HIVMA so we can celebrate your advocacy and encourage others to participate.
- Don’t hesitate to contact IDSA and HIVMA staff at email@example.com with questions, or if you need additional resources.
Questions for Candidates
Introduce your questions with the context provided for each topic, and ask as many as you can. An easy-to-download and print version of the below list can be found here.
Antibiotic resistance is swiftly diminishing our ability to fight once easily treatable infections while the antibiotic pipeline has collapsed. Resistant infections kill up to 162,000 people in the U.S. annually, with the prediction of 10 million people dying globally by 2050 unless change occurs. Medical advances that include transplantation and cancer therapy are threatened by antibiotic resistance.
- What commitments can you make to address this threat to promote appropriate antibiotic use and invest in the research and development of new antibiotics?
- Will you commit to new investments in antibiotic R&D, new policies to establish antibiotic stewardship in all health care facilities, and new resources for surveillance and prevention?
Fewer physicians now enter the fields of ID and HIV, in part due to high medical school debt coupled with low compensation relative to other specialties. A U.S. Centers for Disease Control and Prevention study predicted a shortfall in HIV physicians beginning this year.
- What will you do to ensure we have the ID / HIV workforce needed to respond to outbreaks, prevent and treat life-threatening infections and drive innovation?
- Will you commit to re-evaluating and recalibrating reimbursement for cognitive care services and advancing new payment models to ensure ID and HIV physicians are fairly compensated?
We have the prevention and treatment tools in-hand to end HIV as an epidemic in the U.S. and yet new HIV infections are not diminishing, and the U.S. ranks last among high-income countries in rates of viral suppression among people living with HIV. Hepatitis C virus can now be cured, but in the U.S. new hepatitis C cases increased 3.5-fold from 2010 to 2016 largely due to the opioid epidemic, and barriers to care remain high.
- Will you commit to ending HIV as an epidemic in the U.S.?
- Will you commit to eliminating the hepatitis C virus in the U.S.?
- How will you expand access to HIV prevention for the populations at highest risk including young gay men of color and transgender individuals?
- How will you decrease the cost of HIV treatment and reduce barriers to hepatitis C treatment?
- What actions will you take to reduce stigma and discrimination as barriers to preventing and treating communicable diseases, including HIV and hepatitis C?
The opioid epidemic is driving significant increases across the U.S. in viral hepatitis, HIV, endocarditis, which is an infection of the heart valve, as well as other serious and life-threatening infections.
- What will you do to address infectious diseases associated with injection drug use?
- Will you support the full spectrum of effective harm reduction strategies including expanding syringe services programs and allowing safe injection sites where approved by the local jurisdiction?
- Will you commit to sustaining funding to track and respond to infections linked to injection drug use?
- How would you integrate substance use disorder treatment and infectious diseases prevention and treatment to reduce deaths due to drug use and to improve health outcomes?
Vaccines are among our most effective public health tools, yet vaccine hesitancy due to misinformation and healthcare barriers has fueled the measles resurgence and limits prevention of serious illnesses that include influenza, shingles, pertussis, and hepatitis A and B.
Sexually transmitted infections are skyrocketing, in part due to a weakening public health system and the opioid epidemic. This includes chlamydia, gonorrhea and syphilis, including infants born with syphilis, where cases more than doubled from 2013 to 2017.
- How will you address this growing epidemic?
- How will you ensure increased and stable funding to support a robust public health workforce and infrastructure throughout the country?
- How will you reduce barriers to STD screening and treatment including the high cost of laboratory testing and of Penicillin benzathine, which is used to treat syphilis?
With rising rates of STDs and HCV, ID and HIV providers face challenges providing effective treatment when their patients face cost barriers.
Outbreaks of emerging and reemerging infectious diseases across the globe, including the current COVID-19 outbreak in Wuhan, China, spur community destabilization and present threats of global spread.
The U.S.-led progress in the global response to HIV, tuberculosis and malaria is at risk of stalling. Despite being preventable and curable, tuberculosis is the leading infectious disease killer globally, is facilitated by HIV and infects 16 million people worldwide.
Climate change is a public health emergency with impacts on human health and raised risks of increased waterborne, zoonotic (animal-related), and vector (mosquito, tick, flea)-borne infectious diseases, as well as infections related to population displacement and severe weather events. Major storms and rising sea levels could lead to cholera. Mosquitos could spread, placing new populations at risk of dengue, Zika, and Lyme disease. Influenza strains could become increasingly diverse as animals, vectors, and humans are forced into closer contact.
- Will you commit to advancing policies that decrease greenhouse gas emissions and promote adaptation and resilience for the impacts of climate change?
- Will you commit to increasing resources for public health infrastructure and research to specifically respond to the infectious diseases impacts of climate change?